Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours

Insights into Imaging

Volumn 4, Issue 5, 2013, Pages 691-700

  Albazaz, Raneem ^a   Patel, Chirag N ^a   Chowdhury, Fahmid U ^a   Scarsbrook, Andrew F ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

18F fluoro 2 deoxy D glucose positron emission tomography computed tomography; Biliary tumours; Cholangiocarcinoma; Gallbladder carcinoma

Indexed keywords

EID: 84884574118     PISSN: None     EISSN: 18694101     Source Type: Journal    
DOI: 10.1007/s13244-013-0268-2     Document Type: Article

References (23)

1. Alberts SR, Gores GJ, Kim GP et al (2007) Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin Proc 82: 628-637.
2. Gaujoux S, Allen PJ (2010) Role of staging laparoscopy in peri-pancreatic and hepatobiliary malignancy. World J Gastrointest 2: 283-290.
3. Weitz J, D'Angelica M, Jarnagin W, Gonen M, Fong Y, Blumgart L, Dematteo R (2004) Selective use of diagnostic laparoscopy prior to planned hepatectomy for patients with hepatocellular carcinoma. Surgery 135: 273-281.
4. Goere D, Wagholikar GD, Pessaux P et al (2006) Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 20: 721-725.
5. Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, Israel O (2004) PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 45: 1640-1646.
6. Votrubova J, Belohlavek O, Jaruskova M et al (2006) The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 33: 779-784.
7. Bruzzi JF, Munden RF, Truong MT et al (2007) PET/CT of esophageal cancer: its role in clinical management. Radiographics 27: 1635-1652.
8. Hillner BE, Siegel BA, Shields AF et al (2008) Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med 49: 1928-1935.
9. Corvera CU, Blumgart LH, Akhurst T et al (2008) 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206: 57-65.
10. Petrowsky H, Wildbrett P, Husarik DB et al (2006) Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 45: 43-50.
11. Lee SW, Kim HJ, Park JH et al (2010) Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol 45: 560-566.
12. Hueman MT, Vollmer CM Jr, Pawlik TM (2009) Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 16: 2101-2115.
13. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D (2004) Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8: 90-97.
14. Wakabayashi H, Akamoto S, Yachida S, Okano K, Izuishi K, Nishiyama Y, Maeta H (2005) Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol 31: 1175-1179.
15. Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H (2003) Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol 84: 74-78.
16. Rodríguez-Fernández A, Gómez Río M, Llamas Elvira JM et al (2004) Positron-emission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg 188: 171-175.
17. Kim JY, Kim MH, Lee TY et al (2008) Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 103: 1145-1151.
18. Jadvar H, Henderson RW, Conti PS (2007) [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 31: 223-228.
19. Moon CM, Bang S, Chung JB et al (2008) Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 23: 759-765.
20. Li J, Kuehl H, Grabellus F et al (2008) Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 98: 438-443.
21. Prytz H, Keiding S, Björnsson E, Broomé U, Almer S, Castedal M, Munk OL, Swedish Internal Medicine Liver Club (2006) Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 44: 1572-1580.
22. Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, van Steenbergen W (2005) Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 43: 358-361.
23. 18F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging. Clin Radiol 66: 366-382.